will i still be able to get my compounded semaglutide FDA Warns on Certain Forms of FDA alerts health care providers,

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, activates brain centers that regulate hunger and blood sugar

Establishing healthy eating patterns, staying adequately hydrated, and monitoring how your body responds to the medication are more important initial goals than achieving specific weight loss targets

Discontinuation appears to be multifactorial, with contributors including gastrointestinal side effects (3), treatment cost and access, patient expectations, and tolerability over time

Gather your supplies Before you begin, assemble everything you need in one place

In a head-to-head comparison of the two GLP-1 drugs, adults living with obesity or overweight who were taking Zepbound, the brand name for tirzepatide, lost more than 20% of their weight on average after about a year and half, compared with an average of about 14% weight loss among those taking Wegovy, the brand name for semaglutide